Chai Discovery Secures $400 Million Series C to Accelerate AI‑Designed Antibody Rollout

Chai Discovery secured $400 million Series C funding, announced in 2026, to expand its artificial‑intelligence platform that creates antibody candidates. The capital will support hiring, compute resources, and clinical collaborations aimed at moving designs into trials.

AI‑Designed Antibodies from Chai Discovery have been adopted by several major pharmaceutical companies, marking the first widespread commercial use of machine‑generated biologics. The deals are expected to cut development timelines by several months and lower early‑stage costs.

Industry Impact analysts project that the $400 million infusion could unlock a multi‑billion‑dollar market for AI‑driven biologics, as big pharma integrates these antibodies into pipelines for cancer, autoimmune and infectious disease programs.

Regulatory Outlook the U.S. FDA has indicated a willingness to review AI‑generated antibody data under its emerging biotech framework, which could streamline approvals for Chai Discovery’s pipeline and encourage further investment.